NEC OncoImmunity发布用于发现新HLA等位基因和肿瘤特异性HLA变体的独特HLA分型技术

2022-02-18 国际文传网络

该文献描述了一种进行新HLA等位基因分型和肿瘤HLA表征的新方法，用于指导个性化癌症免疫治疗。

NEC OncoImmunity AS (NOI) 今天公布了一份文献。该文献描述了一种进行新HLA等位基因分型和肿瘤HLA表征的新方法，用于指导个性化癌症免疫治疗。

该计算方法借用传统HLA分型技术的现有优势，从下一代测序数据中进行HLA分型，同时利用NOI的专有突变调用生物信息学来发现新的HLA等位基因和肿瘤特异性HLA变体。

NOI与Ultimovacs ASA合作进行研究，利用深层靶向HLA测序技术和众多供体的血液来验证HLA分型方法。验证结果证实，在分辨率为2位数(1^st field)和4位数(2^nd field)的情况下，HLA分型成功率几乎达到100%。

该方法发表在同行评审期刊《HLA》中。第一作者Anzar和她的同事还展示了该方法如何从个性化癌症疫苗设计时常规使用的标准测序数据中发现了一个获得正式命名的新型HLA等位基因。

NEC OncoImmunity首席科学官Trevor Clancy博士表示：“这种方法是精准免疫治疗领域的一项重要进步。它将帮助HLA分型社区填补全球人类HLA库的空白，并帮助在疾病关联研究中识别新的HLA变体，同时提高HLA分型在器官移植和疫苗设计中的准确性。我们今后将利用我们生物信息学工具箱中的这一独特方法，进一步对HLA等位基因的变异与癌症免疫疗法反应之间的关系进行表征。”

参考文献

标题：Personalized HLA typing leads to the discovery of novel HLA alleles and tumor-specific HLA variants（个性化HLA分型发现新型HLA等位基因和肿瘤特异性HLA变体）

作者：Irantzu Anzar、Angelina Sverchkova、Pubudu Samarakoon、Espen Basmo Ellingsen、Gustav Gaudernack、Richard Stratford和Trevor Clancy

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (6)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=2030420, encodeId=6e1b203042040, content=<a href='/topic/show?id=25079e7287' target=_blank style='color:#2F92EE;'>#Immunity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9772, encryptionId=25079e7287, topicName=Immunity)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Wed Dec 14 11:15:42 CST 2022, time=2022-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021446, encodeId=c3e22021446e8, content=<a href='/topic/show?id=b34e8962db' target=_blank style='color:#2F92EE;'>#HLA等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8962, encryptionId=b34e8962db, topicName=HLA等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1dfd2500156, createdName=12498c24m69暂无昵称, createdTime=Fri Jul 01 17:15:42 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899543, encodeId=578b18995431e, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Aug 10 04:15:42 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044210, encodeId=7c62204421067, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu May 05 05:15:42 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484166, encodeId=81ed14841663a, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Sun Feb 20 12:15:42 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502082, encodeId=e8ac150208272, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Sun Feb 20 12:15:42 CST 2022, time=2022-02-20, status=1, ipAttribution=)]
2022-12-14 12498d2fm51(暂无昵称)

#Immunity#

108 0
[GetPortalCommentsPageByObjectIdResponse(id=2030420, encodeId=6e1b203042040, content=<a href='/topic/show?id=25079e7287' target=_blank style='color:#2F92EE;'>#Immunity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9772, encryptionId=25079e7287, topicName=Immunity)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Wed Dec 14 11:15:42 CST 2022, time=2022-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021446, encodeId=c3e22021446e8, content=<a href='/topic/show?id=b34e8962db' target=_blank style='color:#2F92EE;'>#HLA等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8962, encryptionId=b34e8962db, topicName=HLA等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1dfd2500156, createdName=12498c24m69暂无昵称, createdTime=Fri Jul 01 17:15:42 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899543, encodeId=578b18995431e, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Aug 10 04:15:42 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044210, encodeId=7c62204421067, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu May 05 05:15:42 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484166, encodeId=81ed14841663a, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Sun Feb 20 12:15:42 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502082, encodeId=e8ac150208272, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Sun Feb 20 12:15:42 CST 2022, time=2022-02-20, status=1, ipAttribution=)]
2022-07-01 12498c24m69暂无昵称

#HLA等位基因#

80 0
[GetPortalCommentsPageByObjectIdResponse(id=2030420, encodeId=6e1b203042040, content=<a href='/topic/show?id=25079e7287' target=_blank style='color:#2F92EE;'>#Immunity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9772, encryptionId=25079e7287, topicName=Immunity)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Wed Dec 14 11:15:42 CST 2022, time=2022-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021446, encodeId=c3e22021446e8, content=<a href='/topic/show?id=b34e8962db' target=_blank style='color:#2F92EE;'>#HLA等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8962, encryptionId=b34e8962db, topicName=HLA等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1dfd2500156, createdName=12498c24m69暂无昵称, createdTime=Fri Jul 01 17:15:42 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899543, encodeId=578b18995431e, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Aug 10 04:15:42 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044210, encodeId=7c62204421067, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu May 05 05:15:42 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484166, encodeId=81ed14841663a, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Sun Feb 20 12:15:42 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502082, encodeId=e8ac150208272, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Sun Feb 20 12:15:42 CST 2022, time=2022-02-20, status=1, ipAttribution=)]
2022-08-10 仁医06

#特异性#

89 0
[GetPortalCommentsPageByObjectIdResponse(id=2030420, encodeId=6e1b203042040, content=<a href='/topic/show?id=25079e7287' target=_blank style='color:#2F92EE;'>#Immunity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9772, encryptionId=25079e7287, topicName=Immunity)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Wed Dec 14 11:15:42 CST 2022, time=2022-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021446, encodeId=c3e22021446e8, content=<a href='/topic/show?id=b34e8962db' target=_blank style='color:#2F92EE;'>#HLA等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8962, encryptionId=b34e8962db, topicName=HLA等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1dfd2500156, createdName=12498c24m69暂无昵称, createdTime=Fri Jul 01 17:15:42 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899543, encodeId=578b18995431e, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Aug 10 04:15:42 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044210, encodeId=7c62204421067, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu May 05 05:15:42 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484166, encodeId=81ed14841663a, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Sun Feb 20 12:15:42 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502082, encodeId=e8ac150208272, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Sun Feb 20 12:15:42 CST 2022, time=2022-02-20, status=1, ipAttribution=)]
2022-05-05 1249842em09(暂无昵称)

#NEC#

122 0
[GetPortalCommentsPageByObjectIdResponse(id=2030420, encodeId=6e1b203042040, content=<a href='/topic/show?id=25079e7287' target=_blank style='color:#2F92EE;'>#Immunity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9772, encryptionId=25079e7287, topicName=Immunity)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Wed Dec 14 11:15:42 CST 2022, time=2022-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021446, encodeId=c3e22021446e8, content=<a href='/topic/show?id=b34e8962db' target=_blank style='color:#2F92EE;'>#HLA等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8962, encryptionId=b34e8962db, topicName=HLA等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1dfd2500156, createdName=12498c24m69暂无昵称, createdTime=Fri Jul 01 17:15:42 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899543, encodeId=578b18995431e, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Aug 10 04:15:42 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044210, encodeId=7c62204421067, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu May 05 05:15:42 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484166, encodeId=81ed14841663a, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Sun Feb 20 12:15:42 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502082, encodeId=e8ac150208272, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Sun Feb 20 12:15:42 CST 2022, time=2022-02-20, status=1, ipAttribution=)]
2022-02-20 luckyshitiancai_42705686

#等位基因#

79 0
[GetPortalCommentsPageByObjectIdResponse(id=2030420, encodeId=6e1b203042040, content=<a href='/topic/show?id=25079e7287' target=_blank style='color:#2F92EE;'>#Immunity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9772, encryptionId=25079e7287, topicName=Immunity)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Wed Dec 14 11:15:42 CST 2022, time=2022-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021446, encodeId=c3e22021446e8, content=<a href='/topic/show?id=b34e8962db' target=_blank style='color:#2F92EE;'>#HLA等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8962, encryptionId=b34e8962db, topicName=HLA等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1dfd2500156, createdName=12498c24m69暂无昵称, createdTime=Fri Jul 01 17:15:42 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899543, encodeId=578b18995431e, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Aug 10 04:15:42 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044210, encodeId=7c62204421067, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu May 05 05:15:42 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484166, encodeId=81ed14841663a, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Sun Feb 20 12:15:42 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502082, encodeId=e8ac150208272, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Sun Feb 20 12:15:42 CST 2022, time=2022-02-20, status=1, ipAttribution=)]
2022-02-20 marongnuan

#HLA#

98 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

报道

NEC OncoImmunity发布用于发现新HLA等位基因和肿瘤特异性HLA变体的独特HLA分型技术

相关资讯

拓展阅读

科室

工具

服务